Cargando…

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies

The Omicron variant of SARS-CoV-2 evades antibody-mediated neutralization with unprecedented efficiency. At least three Omicron sublineages have been identified—BA.1, BA.2, and BA.3—and BA.2 exhibits increased transmissibility. However, it is currently unknown whether BA.2 differs from the other sub...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arora, Prerna, Zhang, Lu, Krüger, Nadine, Rocha, Cheila, Sidarovich, Anzhalika, Schulz, Sebastian, Kempf, Amy, Graichen, Luise, Moldenhauer, Anna-Sophie, Cossmann, Anne, Dopfer-Jablonka, Alexandra, Behrens, Georg M.N., Jäck, Hans-Martin, Pöhlmann, Stefan, Hoffmann, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Short Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072809/ https://www.ncbi.nlm.nih.gov/pubmed/35588741 http://dx.doi.org/10.1016/j.chom.2022.04.017

Ejemplares similares

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
por: Hoffmann, Markus, et al.
Publicado: (2022)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
por: Sidarovich, Anzhalika, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
por: Arora, Prerna, et al.
Publicado: (2021)

No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2
por: Arora, Prerna, et al.
Publicado: (2022)

Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
por: Hoffmann, Markus, et al.
Publicado: (2022)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein
por: Arora, Prerna, et al.
Publicado: (2022)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
por: Arora, Prerna, et al.
Publicado: (2022)

The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
por: Arora, Prerna, et al.
Publicado: (2022)

Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
por: Nehlmeier, Inga, et al.
Publicado: (2023)

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
por: Arora, Prerna, et al.
Publicado: (2021)

SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
por: Arora, Prerna, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
por: Hoffmann, Markus, et al.
Publicado: (2023)

Omicron spike protein: a clue for viral entry and immune evasion
por: Behrens, G. M. N., et al.
Publicado: (2022)

Continued Complexity of Mutations in Omicron Sublineages
por: Spratt, Austin N., et al.
Publicado: (2022)

Health workers’ perception vs medically approved COVID-19 infection risk: the risk communication gap: Ellen Kuhlmann
por: Kuhlmann, E, et al.
Publicado: (2022)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Understanding Omicron: Transmissibility, immune evasion and antiviral intervention
por: Hoffmann, Markus, et al.
Publicado: (2022)

Omicron subvariant BA.5 efficiently infects lung cells
por: Hoffmann, Markus, et al.
Publicado: (2023)

Healthcare Workers' Perceptions and Medically Approved COVID-19 Infection Risk: Understanding the Mental Health Dimension of the Pandemic. A German Hospital Case Study
por: Kuhlmann, Ellen, et al.
Publicado: (2022)

Evasion of neutralising antibodies by omicron sublineage BA.2.75
por: Sheward, Daniel J, et al.
Publicado: (2022)

First sequenced cases of Omicron BA.2 sublineage in Ecuador
por: Andrade-Molina, D.A., et al.
Publicado: (2023)

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
por: Hoffmann, Markus, et al.
Publicado: (2021)

Antibody evasion properties of SARS-CoV-2 Omicron sublineages
por: Iketani, Sho, et al.
Publicado: (2022)

Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages
por: Wang, Yuliang, et al.
Publicado: (2023)

Rapid emergence of omicron sublineages expressing spike protein R346T
por: Groenheit, Ramona, et al.
Publicado: (2022)

Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
por: Niewolik, Jacqueline, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
por: Park, Young-Jun, et al.
Publicado: (2022)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
por: Hoffmann, Markus, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_18qhn8ef6cknscv4464at62f1t